Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Director Shareholding

14 Mar 2005 17:00

Ark Therapeutics Group PLC14 March 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) NAME OF COMPANY ARK THERAPEUTICS GROUP PLC 2) NAME OF DIRECTOR NIGEL PARKER 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of an non-beneficial interest 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them. (If notified) 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s) 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary 7) Number of shares/amount of stock acquired 8) Percentage of issued Class 9) Number of shares/amount of stock disposed 10) Percentage of issued Class 11) Class of security 12) Price per share 13) Date of transaction 14) Date company informed 15) Total holding following this notification 16) Total percentage holding of issued class following this notification IF A DIRECTOR HAS BEEN GRANTED OPTIONS BY THE COMPANY PLEASE COMPLETE THE FOLLOWING BOXES 17) Date of grant 12 MARCH 2005 18) Period during which or date on which exercisable 75% EXERCISABLE FROM 12 MARCH 2008, REMAINING 25% EXERCISABLE FROM 12 MARCH 2009. OPTIONS LAPSE ON 11 MARCH 2015 19) Total amount paid (if any) for grant of the option NIL 20) Description of shares or debentures involved: class, number. 350,000 ORDINARY SHARES 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise 96.25 PENCE PER SHARE 22) Total number of shares or debentures over which options held following this notification 4,196,808 ORDINARY SHARES 23) Any additional information 24) Name of contact and telephone number for queries Nick PlummerCompany Secretary+44 (0)20 7388 7722 25) Name and signature of authorised company official responsible for making this notification Nick PlummerCompany Secretary Date of Notification 14 March 2005 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Mar 20101:21 pmRNSEPT Disclosure
10th Mar 201011:52 amRNSEPT Disclosure
10th Mar 20107:00 amRNSFinal Results
9th Mar 20107:00 amRNSResearch Update
8th Mar 20105:34 pmRNSHolding(s) in Company
23rd Feb 20107:00 amRNSResearch Update
19th Feb 20107:00 amRNSRe Agreement
16th Feb 20104:40 pmRNSSecond Price Monitoring Extn
16th Feb 20104:35 pmRNSPrice Monitoring Extension
11th Feb 201011:37 amRNSDirector/PDMR Shareholding
5th Feb 20104:35 pmRNSPrice Monitoring Extension
29th Jan 20103:23 pmRNSTotal Voting Rights
28th Jan 201011:05 amRNSNotice of Results
28th Jan 20107:02 amRNSResearch Update
28th Jan 20107:00 amRNSResearch Update
20th Jan 20103:51 pmRNSEmployee Benefit Trust
5th Jan 20107:00 amRNSArk files for re-examination of Cerepro
22nd Dec 20094:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20094:35 pmRNSPrice Monitoring Extension
18th Dec 200911:56 amRNSEMEA recommendation on Cerepro
15th Dec 20092:29 pmRNSHolding(s) in Company
3rd Dec 20092:41 pmRNSBlocklisting Interim Review
3rd Dec 20092:35 pmRNSHolding(s) in Company
24th Nov 20094:04 pmRNSHolding(s) in Company
11th Nov 20097:00 amRNSInterim Management Statement
14th Oct 20097:00 amRNSResearch Update
2nd Oct 200911:04 amRNSHolding(s) in Company
30th Sep 200910:51 amRNSHolding(s) in Company
29th Sep 20094:32 pmRNSHolding(s) in Company
4th Sep 20097:00 amRNSResearch Update
1st Sep 200912:08 pmRNSDirector/PDMR Shareholding
26th Aug 20097:00 amRNSHalf Yearly Report
26th Aug 20097:00 amRNSResearch Update
13th Jul 20097:00 amRNSArk launches Kerraglove woundcare device
1st Jul 20097:00 amRNSRe Agreement
26th Jun 20092:15 pmRNSHolding(s) in Company
24th Jun 20097:00 amRNSManufacturing Update
17th Jun 20097:00 amRNSRe Agreement
3rd Jun 200911:47 amRNSBlocklisting Interim Review
21st May 20097:00 amRNSTrinam Phase III Study Enrols First Patient
18th May 20097:00 amRNSInterim Management Statement
15th May 20097:00 amRNSCerepro Named Patient Supply approved in Finland
13th May 20094:41 pmRNSSecond Price Monitoring Extn
13th May 20094:35 pmRNSPrice Monitoring Extension
12th May 20097:00 amRNSDirector/PDMR Shareholding
6th May 20094:40 pmRNSSecond Price Monitoring Extn
6th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20097:00 amRNSTrinam(R) Awarded Fast Track Status by FDA
30th Apr 20094:01 pmRNSTotal Voting Rights
30th Apr 200912:00 pmRNSPrestigious European Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.